Archive

01 April 2013, Volume 33 Issue 4 Previous Issue    Next Issue

---

For Selected:

Download Citations EndNote Ris BibTeX

Toggle Thumbnails

Select

Thinking on the prevention，treatment and patient rehabilitation of cardiovascular disease in China. HU Da-yi. 2013, 33(4): 253-255.  Abstract ( )   PDF (903KB) ( )   Abstract：Cardiovascular diseases threaten severely the health of the residents in our country，and also affect social and economic development.The fundamental way to solve this problem is to build a sound modern medical mode of prevention-standardized diagnosis and treatment-rehabilitation and a care system throughout the course of disease.

Select

Knowledge and progress of structural heart disease. ZHU Xian-yang,XIAO Jia-wang. 2013, 33(4): 256-258.  Abstract ( )   PDF (905KB) ( )   Abstract：Structural heart disease is a new subspecialty in cardiovascular field.It refers to anatomic heart or great vessels abnormalities by congenital or acquired factors.The majority of anatomical structure in congenital heart disease can be cured by interventional therapy. hybrid procedure combined with surgery and internal operation,transcatheter aortic valve implantation for aortic stenosis and transcatheter mitralvalve repair for mitral insufficiency have changed the traditional treatment model which show the wide prospects of interventional therapy of structural heart diseases.

Select

Current status in interventional therapy of congenital heart disease in China. JIANG Shi-liang. 2013, 33(4): 259-262.  Abstract ( )   PDF (974KB) ( )   Abstract：Fifteen hundred thousand infants were born with congenital heart disease (CHD) every year in China.Since the first transcatheter therapy of CHD was performed in China in 1984，with the advancement of interventional techniques，the application of Chinas homemade device and the accumulation of clinical experience，we have achieved great progress in transcatheter therapy of CHD in China.From January 2009 to December 2012，a total of 81 645 patients with CHD were treated by interventional therapy，and the technical success rate was 97.69%.The severe complication rate was 0.17%，and the mortality rate was 0.03%.At present，there are 33 training centers of interventional treatment for congenital heart disease in China.Qualitative surveillance of interventional therapy for CHD has been controlled by the Ministry of Health of the Peoples Republic of China.We believe that the practice of interventional therapy for CHD in China will soon be standardized and widely developed in the future，and more and more Chinese patients with CHD will benefit from interventional therapy.

Select

How to select the timing and therapeutic approach for congenital heart disease. GAO Wei. 2013, 33(4): 263-267.  Abstract ( )   PDF (924KB) ( )   Abstract：The severity of congenital heart disease varies and how to select the appropriate timing and therapeutic approach is an important prerequisite to get the best efficacy and reduce the mortality.Percutaneous balloon pulmonic valvuloplasty is the first choice for the management of pulmonary valve stenosis in patients at any age.Either surgery or interventional therapy for aortic valve stenosis is as a palliative treatment in childhood.Percutaneous balloon aortic valvuloplasty or stent implantation is the therapeutic approach for coarctation of the aorta in patients during early childhood and adolescence.Congenital heart diseases with left to right shunt，which develop a significant pulmonary hypertension，need early interventional treatment or surgery.As for the complicated congenital heart diseases，how to determine the timing of surgery and to select surgical approach are based on pulmonary artery pressure，size of pulmonary artery and the existence of hypoxemia.

Select

Management of congenital heart disease complicated with other common diseases. SONG Zhi-yuan,YAO Qing. 2013, 33(4): 268-271.  Abstract ( )   PDF (918KB) ( )   Abstract：Patients with congenital heart disease will easily develop complications such as pulmonary infection，infective endocarditis，heart failure，renal insufficiency，arrhythmia and so on，because of the particularity of the pathological anatomy and pathophysiology.Coexistence of these diseases above in patients not only affects the choice of treatment，but also has a significant impact on the therapeutic efficacy and prognosis.In this paper，the strategies，the principles and the timing of surgical treatment for congenital heart disease combined with pulmonary infection，with infective endocarditis，with heart failure，with renal insufficiency，with arrhythmia，and with those concerned generally，will be systematically elaborated as references for clinicians.

Select

Clinical countermeasures against congenital heart disease in adults. XU Zhong-ying. 2013, 33(4): 272-276.  Abstract ( )   PDF (920KB) ( )   Abstract：Congenital heart disease is common among the newborns，and the incidence rate is about 0.8%.Over the past 30 years，great progress has been made in the diagnosis and treatment of congenital heart disease in children.As a result，many children with such diseases now survive to adulthood.In the United States alone，the population of adults with congenital heart disease，either surgically corrected or uncorrected，is estimated to be increasing at a rate of about 5 percent every year；in 2008 there had be almost 1 million such patients.Currently in China，although there is no statistical data of incidence of adult congenital heart disease，the number of such patients must be huge.This article discusses congenital heart disease from two aspects：acyanotic and cyanotic；and clinical countermeasures against each type will be described.

Select

Treatment of congenital heart disease associated with pulmonary arterial hypertension. ZHOU Da-xin,CHEN Dan-dan. 2013, 33(4): 277-279.  Abstract ( )   PDF (906KB) ( )   Abstract：Pulmonary arterial hypertension (PAH) commonly arises in patients with congenital heart disease (CHD).Management of PAH-CHD can involve surgical correction of the cardiac defect and/or treatment of the PAH.Prostacyclin analogues，phosphodiesterase type-5 inhibitors and bosentan may have benefits in advanced pulmonary vascular disease.Transplantation surgery can be curative but is not without limitations.The timing of intervention in patients with PAH-CHD is important.

Select

Patent foramen ovale and paradoxical embolism can never be wiped out of our sight. HE Lu,ZHANG Yu-shun. 2013, 33(4): 280-283.  Abstract ( )   PDF (924KB) ( )   Abstract：The patent foramen ovale (PFO) persists during fetal life and approximately 1 of every 4 adults.In recent years，PFO has been implicated in the etiology of cryptogenic stroke secondary to paradoxical embolism，migraine headache，platypneaorthodeoxia syndrome and neurologic decompression illness.This article focuses on the relationship between PFO and PDE，the current research status and treatment of PFO-related syndromes，so as to further understand PFO and PDE，thus proposing theoretical evidence for the treatment of PFO-related syndromes.

Select

The interventional treatment of valvular heart disease. QIN Yong-wen,BAI Yuan. 2013, 33(4): 284-288.  Abstract ( )   PDF (936KB) ( )   Abstract：Valvular heart disease is a common heart disease, and the incidence of degenerative valvular disease rate increased year by year, especially the degenerative aortic valve stenosis.Developments in the field of invasive cardiology have led to percutaneous valve repair and replacement becoming a reality.Patients selected for these procedures are deemed too high risk for conventional surgery.They are often elderly,have severe primary valvular disease and multiple co-morbidities.This article summarises these procedures, reviews the published device issues relevant to percutaneous valve repair.

Select

Interpretation of 2013 ACCF/AHA STEMI treatment guidelines. LI Xian-kai,XU Ya-wei. 2013, 33(4): 289-292.  Abstract ( )   PDF (1512KB) ( )   Abstract：Based on the recent published large-scale clinical trials,ACCF/AHA constantly updated guide for the treatment of acute coronary syndrome.Recently,ACCF/AHA STEMI (acute ST-elevation myocardial infarction) guideline was published in Circulation in 2013,of which there were many bright spots,such as the new guideline proposed first medical contact (FMC) to reperfusion treatment time,shifting emergency treatment of STEMI to pre-hospital emergency from hospital treatment,it also stressed the status of P2Y12 inhibitor (prasugrel and ticagrelor) in STEMI patients.The latest guideline provides new evidences for the treatment of STEMI.

Select

Inerpretation and enlightenment of 2012 ESC guideline on the mangement of vavular heart disease. ZENG Rui,ZENG Zhi. 2013, 33(4): 293-295.  Abstract ( )   PDF (909KB) ( )   Abstract：：The 2012 edition of valvular heart disease (VHD) prevention and treatment guideline jointly was issued by the European Society of Cardiology (ESC) and the European Association of Cardiothoracic Surgery (EACTS) in Munich，Germany on the ESC Congress.The guideline update was based on the new clinical evidence collected in the past five years.Major changes include：desalinated the dependence of EuroSCORE and STS score，stressed the importance of establishing the team of heart management for patients，made clear the indications of transcatheter aortic valve implantation (TAVI) and percutaneous edge-to-edge valve repair，and adjusted the strategy of postoperative anticoagulation.The guideline also suggested us that although interventional treatment of VHD had made considerable progress，sometimes making surgery no longer the only treatment of certain valvular disease，it still had many problems such as choice of indications，management of complications，and follow-up and long-term efficacy evaluation of large-sample，multicenter research.It is not recommended to use this treatment in the big- or medium-sized hospitals whose relevant conditions were not yet mature.For the new clinic technology，we should follow the principles of actively exploring and cautiously advancing.